Response: Commentary: An In Silico-In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

Front Immunol. 2021 Jul 13:12:679836. doi: 10.3389/fimmu.2021.679836. eCollection 2021.

Michele Mishto^{1

2}, Guillermo Rodriguez-Hernandez^{1

2}, Jacques Neefjes³, Henning Urlaub^{4

5}, Juliane Liepe⁴

¹ Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.
² Francis Crick Institute, London, United Kingdom.
³ Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center (LUMC), Leiden, Netherlands.
⁴ Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.
⁵ Bioanalytics, Institute of Clinical Chemistry, University Medical Center, Göttingen, Germany.

No abstract available

Keywords: antigen presentation; mass spectrometry; peptide splicing; proteasome; tumor immunology.

Publication types